妊娠期停用他汀与母亲心血管健康及出生结局的全国队列研究
停药与母亲主要不良心脑血管事件风险无显著增加相关(HR 1.00,95%CI 0.72-1.37),且与较低的非活产和低出生体重风险相关,但胎儿结局差异需谨慎解读。
要点
- 孕前停用他汀未增加母亲MACCE风险(HR 1.00,95%CI 0.72-1.37)。
- 高危女性(家族性高胆固醇血症或动脉粥样硬化性心血管病)停药后MACCE风险亦无显著差异。
- 停药与非活产(RR 0.89,95%CI 0.82-0.95)和低出生体重(RR 0.88,95%CI 0.78-0.99)风险降低相关。
核心结论
- 妊娠期停用他汀与母亲心血管风险增加无关,包括高危女性。
- 次要分析提示停药与较低的非活产和低出生体重风险相关,但需谨慎解读。
研究设计与样本
- 全国性队列研究,使用韩国国民健康保险数据库2009至2023年数据。
- 采用倾向评分重叠权重控制混杂,Cox模型估计MACCE风险比,广义线性模型估计妊娠结局风险比。
主要发现
- 7493名(56.0%)继续他汀治疗,5881名(44.0%)在末次月经前停药。
- 停药组与继续组相比,MACCE风险无显著差异(HR 1.00,95%CI 0.72-1.37)。
- 家族性高胆固醇血症亚组(n=2435)MACCE风险无显著差异(HR 0.92,95%CI 0.46-1.85)。
- 动脉粥样硬化性心血管病亚组(n=1879)MACCE风险无显著差异(HR 0.83,95%CI 0.46-1.49)。
- 停药与非活产风险降低相关(RR 0.89,95%CI 0.82-0.95),与低出生体重风险降低相关(RR 0.88,95%CI 0.78-0.99)。
临床怎么用
- 对于孕前使用他汀的女性,妊娠期停药未显示增加母亲心血管风险,可个体化评估。
- 高危女性停药后心血管风险亦无显著增加,但仍需结合临床判断。
- 胎儿结局差异需谨慎解读,不应仅基于此改变临床实践。
局限性
- 观察性设计,胎儿结局差异应谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Discontinuing statin therapy before pregnancy remains challenging, especially in high-risk women. We evaluated the risks of maternal cardiovascular, gestational, and fetal outcomes associated with continuing versus discontinuing statin therapy before the last menstrual period (LMP). METHODS: We conducted a nationwide cohort study using data from the National Health Insurance Database of South Korea collected between 2009 and 2023. Women who used statins for 12 to 24 weeks before their LMP between 2010 and 2022 were stratified by whether they discontinued statins before their LMP. Maternal cardiovascular outcomes were major adverse cardiovascular and cerebrovascular events (MACCE), a composite of myocardial infarction, stroke, coronary revascularization, and cardiovascular death. Gestational and fetal outcomes included preterm delivery, pre-eclampsia/eclampsia, other hypertensive disorders of pregnancy, gestational diabetes, nonlive birth, major congenital malformations, and low birth weight. Propensity scores were estimated from potential confounders, and overlap weighting was applied to control for confounding factors. The weighted hazard ratio for MACCE was estimated using a Cox proportional hazards model. Weighted risk ratios for gestational outcomes were estimated using generalized linear models with 95% CIs. RESULTS: Among 13 374 women with preconception statin use, 7493 (56.0%) continued statin therapy beyond their LMP, and 5881 (44.0%) discontinued statin therapy before their LMP. Compared with continued statin, discontinued statin before the LMP was not associated with an increased risk of maternal MACCE (hazard ratio, 1.00 [95% CI, 0.72-1.37]). Even among women with established familial hypercholesterolemia (n=2435; hazard ratio, 0.92 [95% CI, 0.46-1.85]) or atherosclerotic cardiovascular disease (n=1879; hazard ratio, 0.83 [95% CI, 0.46-1.49]), there was no significant difference in the risk of MACCE between the 2 groups. Statin discontinuation was associated with a lower risk of nonlive birth (risk ratio, 0.89 [95% CI, 0.82-0.95]) and low birth weight (risk ratio, 0.88 [95% CI, 0.78-0.99]). CONCLUSIONS: In this nationwide cohort, discontinuation of statins at pregnancy was not associated with increased maternal cardiovascular risk, including among high-risk women. Secondary analyses suggested differences in fetal outcomes between groups; however, these findings should be interpreted cautiously given the observational design.
引用
- Cho Y, Kang D, Lim H, et al. Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study. Circulation. 2026. PMID: 41574427. doi:10.1161/CIRCULATIONAHA.125.078919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。